Fig. 7.

Fig. 7.

Vegfa/Vegfr signalling is necessary for ISV lumenisation maintenance and DLAV formation. (A) Representative images of missing ISV, fully lumenised ISV and not fully lumenised ISV at 48 hpf. Quantifications of these phenotypes are presented in B and C. Dashed line indicates expected location of missing ISV. Inset on right is magnification of boxed area. (B) Bilateral quantifications of the percentage of missing ISVs in the trunk of 48 hpf MO-CTL (5 ng) [n=29 (0 nM ZM32881), n=28 (50 nM ZM32881)], MO-svep1 (5 ng) [n=29 (0 nM ZM32881), n=26 (50 nM ZM32881)] embryos treated with 1× (0.014%) tricaine and 0 nM or 50 nM ZM32881 from 30 to 48 hpf (N=3). (C) Bilateral quantifications of the percentage of ISVs lumenised dorsally to ventrally in the trunk of 48 hpf MO-CTL (5 ng) [n=29 (0 nM ZM32881), n=28 (50 nM ZM32881)], MO-svep1 (5 ng) [n=29 (0 nM ZM32881), n=26 (50 nM ZM32881)] embryos treated with 1× (0.014%) tricaine and 0 or 50 nM ZM32881 from 30 to 48 hpf (N=3). (D) Bilateral quantifications of the percentage of gaps in the DLAV at 48 hpf in embryos treated with 2× (0.028%) tricaine and 0 (n=22) or 50 nM (n=21) ZM32881 from 30 to 48 hpf (N=3). (E) Bilateral quantifications of the percentage of lumenised segments in the DLAV at 48 hpf in embryos treated with 2× (0.028%) tricaine and 0 nM (n=22) or 50 nM (n=21) ZM32881 from 30 to 48 hpf (N=3). (F) Bilateral quantifications of the percentage of ISVs lumenised dorsally to ventrally in the trunk of 48 hpf in embryos treated with 2× (0.028%) tricaine and 50 nM (n=21) ZM32881 from 30 to 48 hpf (N=3). (G) Bilateral quantifications of the percentage of missing ISVs in the trunk of 48 hpf in embryos treated with 2× (0.028%) tricaine and 50 nM (n=21) ZM32881 from 30 to 48 hpf (N=3). Data are mean±s.d. Mann–Whitney test.